On 02 July 2015, the FDA made a decision concerning the Theranos Herpes Simplex Virus-1 IgG Assay.
The 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY concludes:
> The submitted information in this premarket notification is complete and supports a substantial equivalence decision.